Revenues surge at Salix; quarterly performance tops Street expectations
Salix
On The Web
Site Search
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
RALEIGH, N.C. – Despite a sharp increase in revenues, Salix Pharmaceuticals (Nasdaq: SLXP) reported a larger third quarter loss than in 2008 on Monday.
However, the company which focuses on gastrointestinal drugs, still beat Wall Street expectations.
Salix revenues jumped 53 percent to $65.7 million with a traveler’s diarrhea drug, Xifaxan, delivering nearly double its 2008 revenues at $43 million.
Still, Salix reported a loss of $7.3 million, or 15 cents per share. Analysts polled by Thomson Reuters expected a 29-cent loss.
Driving up losses were increased costs for sales as well as research and development.
Among the expenses was a $5 million payment for acquisition of U.S. rights to a bioadhesive technology.
Featured
Hot Off The Wire
- Hot Off the Wire – Google slashes Nexus One termination fee; MySpace Music tunes up audio ads; Barry Diller’s IAC beats Street
- Hot Off the Wire – Man convicted in first economic espionage case; iPhone market share grows; Electronic Arts shares falter after revenue forecast; Phone company wants to charge Google
- FairPoint looks to cut debt by two thirds with bankruptcy plan
E-mail Preferences
The Skinny
- Gears of War 3 coming? EA discloses Epic game for 2011
- Nagoya University bridges East, West with Nu Tech event
- E-mail services provider iContact investigating a hack attack
- Cyberespionage? Cyberslueths disclose Lenovo’s 2010 ‘roadmap’
- Tech recovery is at hand, analysts tells N.C. IT execs
- Believe it - Triangle region lands record $1.9B in business projects
- Epic Games’ heroes take their guns to a new world – ‘Lost Planet 2’
- IPO rewards: Motricity CEO gets a $75,000 raise in new contract
- IT recession over? Spending will rebound, analysis firm says
- Google vs. the Dragon – War over words could ignite into flames